Adalimumab ========== Injection 20 mg in 0.2 mL pre-filled syringe SaveGeneral schedule PBS item code15539WMaximum quantity2 units Repeats5 More detailsProgramGE AdministrationINJECTION Benefit typeS Brands - Yuflyma[TGA record](https://www.tga.gov.au/resources/artg/438910 "TGA ARTG record 438910")[CMI (PDF)](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024-CMI-01434-1 "Consumer Medicine Information (PDF)")[PI (PDF)](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024-PI-01432-1 "Product Information (PDF)") Dispensed price for maximum quantity (DPMQ)3 pricesYuflyma · Community pharmacy$606.96 Yuflyma · Private hospital$586.35 Yuflyma · Public hospital$569.14 Restrictions & indications ------------------------------ Streamline authority code15445 Uveitis (Non-Infectious, Vision threatening) - Continuing treatment Show full PBS criteriaHide full PBS criteriaVision threatening non-infectious uveitis Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug for this condition; AND The treatment must not exceed 24 weeks under this restriction per authority application; AND Must be treated by an ophthalmologist, rheumatologist or immunologist with expertise in uveitis; or Must be treated by a medical practitioner who has consulted at least one of the above mentioned specialist types, with agreement reached that the patient should be treated with this pharmaceutical benefit on this occasion. An adequate response to treatment is defined as: (a) Sustained reduction in inflammation defined as a 2-step decrease from baseline in Standardisation of Uveitis Nomenclature (SUN) criteria for anterior chamber or vitreous haze; or (b) Sustained quiescence of inflammation defined as Standardisation of Uveitis Nomenclature (SUN) criteria less than or equal to 0.5+ anterior chamber or vitreous haze, absence of active vitreous or retinal lesions or vitreous cells; or (c) Sustained corticosteroid sparing effect, allowing reduction in prednisone to less than 7.5 mg daily; or (d) Reduction in frequency of ocular attacks to less than or equal to 1 per year (patients with Behcet's disease only) The patient remains eligible to receive continuing treatment with the same biological medicine in courses of up to 24 weeks providing they continue to sustain an adequate response. It is recommended that a patient be reviewed in the month prior to completing their current course of treatment. Notes (4)Pharmaceutical benefits that have the form adalimumab 20 mg/0.2 mL syringes and pharmaceutical benefits that have the form adalimumab 20 mg/0.4 mL syringes are equivalent for the purposes of substitution Pharmaceutical benefits that have a pack size of 1 may be substituted for pharmaceutical benefits that have a pack size of 2, in combinations equivalent to the maximum quantity number of units. No increase in the maximum quantity or number of units may be authorised. No increase in the maximum number of repeats may be authorised. Prescribing notes (4)No increase in the maximum quantity or number of units may be authorised. No increase in the maximum number of repeats may be authorised. Pharmaceutical benefits that have the form adalimumab 20 mg/0.2 mL syringes and pharmaceutical benefits that have the form adalimumab 20 mg/0.4 mL syringes are equivalent for the purposes of substitution Pharmaceutical benefits that have a pack size of 1 may be substituted for pharmaceutical benefits that have a pack size of 2, in combinations equivalent to the maximum quantity number of units. Other listings for Adalimumab Injection 20 mg in 0.2 mL pre-filled syringe -------------------------------------------------------------------------- [General12371DMaximum 2 units · 3 repeats - Ulcerative Colitis (Moderate to severe) - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply - Ulcerative Colitis (Moderate to severe) - Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) - Ulcerative Colitis (Moderate to severe) - Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - Ulcerative Colitis (Moderate to severe) - Initial treatment - Initial 1 (new patient)](/p/12371D)[General12407BMaximum 2 units · 3 repeats - Crohn Disease (Severe) - Initial 2 (change or recommencement of treatment after a break in targeted therapy of less than 12 months) - Crohn Disease (Severe) - Initial 1 (new patient) - Crohn Disease (Severe) - Initial 3 (recommencement of treatment after a break in targeted therapy of more than 12 months)](/p/12407B)[General12337HMaximum 2 units · 5 repeats - Ulcerative Colitis (Moderate to severe) - Continuing treatment - balance of supply - Ulcerative Colitis (Moderate to severe) - First continuing treatment](/p/12337H)[Public12406YMaximum 2 units · 0 repeats - Juvenile Idiopathic Arthritis (Active, Severe) - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply - Juvenile Idiopathic Arthritis (Active, Severe) - Initial treatment - Initial 1 (new patient) - Juvenile Idiopathic Arthritis (Active, Severe) - Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - Juvenile Idiopathic Arthritis (Active, Severe) - Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)](/p/12406Y) Data source: [Australian Government PBS Schedule](https://www.pbs.gov.au/info/browse/download) · Record updated 30 September 2026. Verify current listing and prescribing requirements on the [official PBS website](https://www.pbs.gov.au/).